Daiichi Sankyo’s Japan Sales Up 8% After Long-Term Prescription Bans Lifted
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo’s 2012 Japan sales were ¥442.5 billion, thanks to prescription limits were lifted for Alzheimer drug Memary (memantine) and PPI Nexium (esomeprazole).